Skip to content

Study · Case report or series · n = 1 · 2022

1 result

Semaglutide-Associated Acute Interstitial Nephritis: A Case Report.

Borkum M, Lau W, Blanco P, Farah M

Kidney medicine29 Oct 2022Cited by 11 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a patient with no underlying chronic kidney disease, a semaglutide dose increase was temporally related to drug-associated acute interstitial nephritis that required hemodialysis.

    In plain wordsIn one patient with healthy kidneys, acute kidney inflammation needing dialysis followed a semaglutide dose increase.

    Outcome
    IncreaseAcute interstitial nephritis requiring hemodialysis
    Study

    n = 1

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ours is a case of drug-associated acute interstitial nephritis requiring hemodialysis temporally related to a semaglutide dose increase.
    1 context sentence
    Summary · context
    This case is unique as the index patient had no underlying CKD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.